A method to deliver multiple antibodies for HIV-1 treatment
Official title: coRNAucopia - A Method to Deliver Multiple bNAbs in the Same RNA
Funded at Lynntech, INC. · NIH-11171822 · Data updated 2026-11-12
This study is exploring a new way to deliver a combination of powerful antibodies in one shot to help improve treatment for people living with HIV-1, making it easier and more effective to fight the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lynntech, INC. NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | August 15, 2024 |
| Project end | August 14, 2025 |
| Funding year | 2024 |
| Award (this year) | $300,000 |
| NIH project number | 75N93024C00049-0-9999-1 |
| Project ID | NIH-11171822 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for HIV-1 infection or those living with HIV-1 who may benefit from enhanced antibody treatments.
✕Less likely to help
Patients who are not at risk for HIV-1 or those who are already effectively managing their HIV-1 infection with current therapies may not benefit from this research.
What this research studies
This research focuses on developing a new method to deliver multiple broadly neutralizing antibodies (bNAbs) in a single RNA molecule to enhance the treatment of HIV-1. By engineering these antibodies, the research aims to improve their effectiveness, increase their presence in body tissues, and extend their duration of action. The approach addresses challenges such as complex drug delivery and the need for larger injection volumes, ultimately aiming to provide better protection against HIV-1 infection.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HIV-1, potentially reducing the risk of infection.
How similar studies have gone: Previous research has shown promise in the development of broadly neutralizing antibodies for HIV-1, indicating that this approach has potential based on earlier successes.
Where this research is happening
-
Lynntech, INC.
College Station, United States Active
Researchers
- Principal investigator: Harlow, Mark Lee — Lynntech, INC.
- Study coordinator: Harlow, Mark Lee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.